ENTX Strangle Strategy

ENTX (Entera Bio Ltd.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

ENTX (Entera Bio Ltd.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $80.3M, a beta of 1.49 versus the broader market, a 52-week range of 0.91-3.22, average daily share volume of 1.0M, a public-listing history dating back to 2018, approximately 18 full-time employees. These structural characteristics shape how ENTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.49 indicates ENTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on ENTX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ENTX snapshot

As of June 29, 2026, spot at $1.63, ATM IV 23.70%, IV rank 1.26%, expected move 6.79%. The strangle on ENTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on ENTX specifically: ENTX IV at 23.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a ENTX strangle, with a market-implied 1-standard-deviation move of approximately 6.79% (roughly $0.11 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ENTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on ENTX should anchor to the underlying notional of $1.63 per share and to the trader's directional view on ENTX stock.

ENTX strangle setup

The ENTX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ENTX near $1.63, the first option leg uses a $1.71 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ENTX chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ENTX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$1.71	N/A
Buy 1	Put	$1.55	N/A

ENTX strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ENTX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ENTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on ENTX

Strangles on ENTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ENTX chain.

ENTX thesis for this strangle

The market-implied 1-standard-deviation range for ENTX extends from approximately $1.52 on the downside to $1.74 on the upside. A ENTX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ENTX IV rank near 1.26% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ENTX at 23.70%. As a Healthcare name, ENTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ENTX-specific events.

ENTX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ENTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ENTX alongside the broader basket even when ENTX-specific fundamentals are unchanged. Always rebuild the position from current ENTX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ENTX?: A strangle on ENTX is the strangle strategy applied to ENTX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ENTX stock trading near $1.63, the strikes shown on this page are snapped to the nearest listed ENTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ENTX strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ENTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 23.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ENTX strangle?: The breakeven for the ENTX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ENTX market-implied 1-standard-deviation expected move is approximately 6.79%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ENTX?: Strangles on ENTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ENTX chain.
How does current ENTX implied volatility affect this strangle?: ENTX ATM IV is at 23.70% with IV rank near 1.26%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.